Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

ajmc.com image

News from ajmc.com

ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

ajmc.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ajmc.com

Where is ajmc.com located?ajmc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ajmc.com News

Affordable Care Act enrollees say expiring subsidies will hit them hard

Mike Johnson · United States

Affordable Care Act enrollees say expiring subsidies will hit them hard

86% Center coverage: 41 sources

The Senate rejected two proposals to address the problem and an emerging package from House Republicans does not include an extension.See the Story

COVID shot reduces risk of severe illness, premature birth in pregnancy, study says

Vaccines · Canada

COVID shot reduces risk of severe illness, premature birth in pregnancy, study says

61% Left coverage: 38 sources

A new study says the COVID-19 vaccine protects pregnant women from getting severely ill or giving birth prematurely.See the Story

AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment — REUTERS / FES376

FDA · United States

AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment

80% Center coverage: 10 sources

(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. Approval was based on results...See the Story

Blindspots

COVID shot reduces risk of severe illness, premature birth in pregnancy, study says

COVID shot reduces risk of severe illness, premature birth in pregnancy, study says

COVID shot reduces risk of severe illness, premature birth in pregnancy, study says

Breaking News Topics Related to ajmc.com